Metformin, a first-line medication for type 2 diabetes associated with obesity, lowers blood sugar levels, reduces inflammation, improves insulin sensitivity, and improves endothelial function in rodents and humans [20,21,22,23,24,25,26]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.